Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AKR1C3 | P42330 | 12/20 | 0.50 |
| ▸ | AKR1C2 | P52895 | 12/20 | 0.50 |
| ▸ | AKR1B10 | O60218 | 2/20 | 0.50 |
| ▸ | AKR1B1 | P15121 | 2/20 | 0.50 |
| ▸ | AKR1C4 | P17516 | 2/20 | 0.50 |
| ▸ | AKR1C1 | Q04828 | 2/20 | 0.50 |
| ▸ | PKM | P14618 | 1/20 | 0.50 |
| ▸ | POLB | P06746 | 1/20 | 0.47 |
| ▸ | HSD17B1 | P14061 | 2/20 | 0.46 |
| ▸ | HTT | P42858 | 1/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.44 |
| ▸ | GABRP | O00591 | 1/20 | 0.43 |
| ▸ | GABRD | O14764 | 1/20 | 0.43 |
| ▸ | GABRA1 | P14867 | 1/20 | 0.43 |
| ▸ | GABRB1 | P18505 | 1/20 | 0.43 |
| ▸ | GABRG2 | P18507 | 1/20 | 0.43 |
| ▸ | GABRB3 | P28472 | 1/20 | 0.43 |
| ▸ | GABRA5 | P31644 | 1/20 | 0.43 |
| ▸ | GABRA3 | P34903 | 1/20 | 0.43 |
| ▸ | GABRA2 | P47869 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL277909 | 0.90 | ALDH1A1 (0.54) | POLBHTTALDH1A1GABRPGABRD | |
| SCHEMBL10936584 | 0.89 | HSD17B1 (0.54) | PKMHSD17B1HTTALDH1A1 | |
| SCHEMBL2000489 | 0.85 | RXRA (0.44) | HSD17B1ALDH1A1GABRPGABRDGABRA1 | |
| SCHEMBL13714204 | 0.85 | AKR1C3 (0.51) | AKR1C3AKR1C2AKR1B10AKR1B1AKR1C4 | |
| SCHEMBL14360615 | 0.83 | ALDH1A1 (0.47) | HTTALDH1A1GABRPGABRDGABRA1 | |
| SCHEMBL11150842 | 0.80 | HSP90AA1 (0.46) | ALDH1A1GABRPGABRDGABRA1GABRB1 | |
| SCHEMBL11146746 | 0.80 | KDM4E (0.53) | ALDH1A1 | |
| SCHEMBL6272280 | 0.80 | ALDH1A1 (0.46) | POLBHTTALDH1A1GABRPGABRD | |
| SCHEMBL3385017 | 0.80 | ALDH1A1 (0.52) | AKR1C3AKR1C2ALDH1A1GABRPGABRD | |
| SCHEMBL27700587 | 0.80 | AKR1C3 (0.46) | AKR1C3AKR1C2AKR1B10AKR1B1AKR1C4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9828338-B2 | Carbamate derivatives of lactam based N-acylethanolamine acid amidase (NAAA) inhibitors | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2017-11-28 | — | — | US | disclosed |
| US-20160068482-A1 | CARBAMATE DERIVATIVES OF LACTAM BASED N-ACYLETHANOLAMINE ACID AMIDASE (NAAA) INHIBITORS | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA | 2016-03-10 | — | — | US | disclosed |
| WO-2014144836-A2 | CARBAMATE DERIVATIVES OF LACTAM BASED N-ACYLETHANOLAMINE ACID AMIDASE (NAAA) INHIBITORS | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2014-09-18 | — | — | WO | disclosed |
| WO-2010019828-A1 | GLUCAGON RECEPTOR ANTAGONISTS | METABASIS THERAPEUTICS, INC. (US) | 2010-02-18 | — | — | WO | disclosed |
| US-6962920-B2 | Pyrimidine derivatives and methods of making and using these derivatives | DUQUESNE UNIVERSITY OF THE HOLY GHOST (US) | 2005-11-08 | — | — | US | disclosed |
| US-20040039000-A1 | Novel pyrimidine derivatives and methods of making and using these derivatives | GANGJEE ALEEM (US) | 2004-02-26 | — | — | US | disclosed |
| US-6537999-B2 | Furopyrimidines and pyrrolopyrimidines; treating cancer, and secondary infections caused by Pneumocystis carinii and Toxoplasmosis gondii in immunocompromised patients. | DUQUESNE UNIVERSITY OF THE HOLY GHOST | 2003-03-25 | — | — | US | disclosed |
| US-20020052384-A1 | Novel pyrimidine derivatives and methods of making and using these derivatives | GANGJEE ALEEM (US) | 2002-05-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160068482-A1 | CARBAMATE DERIVATIVES OF LACTAM BASED N-ACYLETHANOLAMINE ACID AMIDASE (NAAA) INHIBITORS | NAAA, FAAH, FAAH2 | AKR1C3 3107/4885AKR1C2 2865/4885AKR1B10 2816/4885 |
| US-20040039000-A1 | Novel pyrimidine derivatives and methods of making and using these derivatives | TYMP, TYMS, DPYD | AKR1C3 1015/4885AKR1C2 1409/4885AKR1B10 1666/4885 |
| US-20020052384-A1 | Novel pyrimidine derivatives and methods of making and using these derivatives | TYMP, TYMS, DPYD | AKR1C3 1015/4885AKR1C2 1409/4885AKR1B10 1666/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.